An APOE4 result describes a higher statistical risk of Alzheimer's, not a diagnosis and not a certainty. In a 1997 meta-analysis of Caucasian people from clinic- or autopsy-based studies, the odds of Alzheimer's were OR=3.2 for ε3/ε4 and OR=14.9 for ε4/ε4 compared with ε3/ε3, and the link was weaker in the African American and Hispanic groups studied.
What the studies found
A 1997 meta-analysis in JAMA pooled data from 40 research teams on 5930 patients with probable or definite Alzheimer's disease and 8607 controls without dementia. Among Caucasian subjects from clinic- or autopsy-based studies, the risk of Alzheimer's was significantly increased for genotypes ε2/ε4 (OR=2.6), ε3/ε4 (OR=3.2) and ε4/ε4 (OR=14.9), and decreased for ε2/ε3 (OR=0.6), relative to ε3/ε3. The authors concluded that the ε4 allele is a major risk factor in all ethnic groups studied, across all ages between 40 and 90 years, and in both men and women.
The size of the link differed by group. In a 1998 JAMA study of 1079 Medicare recipients in New York City followed for 5 years, the relative risk of Alzheimer's with 1 or more copies of ε4 was 2.5 among whites but 1.0 among African Americans and 1.1 among Hispanics. Without ε4, the cumulative risk to age 90 was 4 times higher for African Americans and 2 times higher for Hispanics than for whites, and the authors concluded that African Americans and Hispanics have an increased frequency of Alzheimer's regardless of their APOE genotype.
For people who already have memory problems, the result is a weak predictor. A 2011 meta-analysis of 35 prospective cohorts of people with MCI (6095 subjects, of whom 1236 progressed to AD-type dementia after 2.9 years of follow-up) found that ε4 carriers had an OR of 2.29 for progressing, with sensitivity 0.53 and specificity 0.67. The authors concluded that the low sensitivity and positive predictive value make genotyping of limited value for predicting AD-type dementia in clinical practice.
- Study
- Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis
Carrying ε4 on both chromosomes behaves differently in a 2024 Nature Medicine analysis of data from the National Alzheimer's Coordinating Center and 5 large cohorts (3,297 individuals for the pathological study and 10,039 for the clinical study). Almost all APOE4 homozygotes showed Alzheimer's pathology, by age 65 nearly all had abnormal amyloid levels in cerebrospinal fluid and 75% had positive amyloid scans, and symptom onset was earlier in APOE4 homozygotes, at 65.1. The authors concluded that APOE4 homozygotes represent a genetic form of the disease.
On how people feel after learning a result, a 2009 randomized trial in the New England Journal of Medicine gave 162 asymptomatic adults who had a parent with Alzheimer's either their APOE result or nothing. There were no significant differences between the groups in anxiety, depression or test-related distress over 1 year, although the ε4-negative subgroup had a significantly lower level of test-related distress than the ε4-positive subgroup (P=0.01). A 2026 randomized trial among Latinos in New York City (194 disclosure, 180 non-disclosure) also found no clinically significant adverse psychological effects of disclosure.
- Studies
- Disclosure of APOE genotype for risk of Alzheimer's disease
- Psychological impacts of APOE genotype disclosure among Latinos in New York City: a randomized controlled trial
A 2026 JAMA Network Open cohort study of cognitively unimpaired adults (3414 individuals, mean age 68.8) found group mean IES scores, a measure of intrusive thoughts, below clinically significant thresholds. Even so, learning ε4 homozygosity was associated with higher scores (12.7) than heterozygosity (9.1), and heterozygosity with higher scores than noncarrier status (6.2).
What remains uncertain
An odds ratio describes how much more common the disease was in a group, not what will happen to one person. The 2011 meta-analysis found that ε4 status was a moderate signal that misses many people who go on to dementia, and the 1998 study found a higher frequency of Alzheimer's among African American and Hispanic participants regardless of APOE genotype.
- Studies
- Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis
- The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics
The 1997 authors state that the association between ε4 and Alzheimer's in African Americans requires clarification and that the attenuated effect in Hispanics should be investigated further. The risk figures come from specific samples (clinic- or autopsy-based studies; one New York City community), so they should not be applied to a person's own ancestry or family without care.
The disclosure trials followed people for about 1 year and in specific groups (adults with a parent with Alzheimer's; a Latino cohort in New York City), and the cohort study measured short-term distress. The library holds no study of long-term feelings or choices after an APOE result in the general population.
- Studies
- Disclosure of APOE genotype for risk of Alzheimer's disease
- Psychological impacts of APOE genotype disclosure among Latinos in New York City: a randomized controlled trial
- Amyloid Imaging and APOE Genotype Disclosure and Short-Term Psychological Distress
Some anti-amyloid trial analyses report results by ε4 status, including one of lecanemab in ε4 non-carriers and heterozygotes. How a result bears on testing or treatment is a decision to make with a clinician or genetic counsellor who knows the person and their family.
This page describes what published studies in alzhub's library report. It is not medical advice and does not apply to any one person. Where a decision would follow, a clinician who knows the person is the one who can say what a result or a choice means for them.
Questions
- Does having APOE4 mean I will get Alzheimer's?
- No. APOE4 describes higher risk, not certainty. A meta-analysis of 35 cohorts of people with MCI concluded that the low sensitivity and positive predictive value make genotyping of limited value for predicting AD-type dementia in clinical practice.
- Is carrying ε4/ε4 different from carrying ε3/ε4?
- In a 1997 meta-analysis of Caucasian subjects from clinic- or autopsy-based studies, the odds of Alzheimer's were OR=14.9 for ε4/ε4 and OR=3.2 for ε3/ε4, relative to ε3/ε3.
- Does the risk from APOE4 differ by ancestry?
- Studies report that it can. In a 1998 study, the relative risk with 1 or more copies of ε4 was 2.5 among whites, 1.0 among African Americans and 1.1 among Hispanics.
- Does learning an APOE result cause distress?
- In a 2009 randomized trial of 162 asymptomatic adults, there were no significant differences in anxiety, depression or test-related distress between those told their result and those not told, although test-related distress was lower among those who learned they were ε4-negative.
Read on
Last updated